Assessing Diabetic Foot Ulcer Microcirculation With High-frequency Contrast Enhanced Ultrasound
- Disease/Condition
- Diabetes Mellitus
- Study type
- Observational
- Primary sponsor
- First Affiliated Hospital of Wenzhou Medical University
- Location
- Wenzhou, China
- Phase
- N/A
- Start date
- Jul 01, 2024
- End date
- Dec 01, 2026
- Enrollment
- 100 participants
H-CEUS score
The objective of this observational study is to investigate and validate the utility of
 high-frame-rate ultrasound imaging technology for dynamic observation of the blood perfusion
 process at the site of ulcer wounds in real-time, focusing on patients with Diabetic Foot
 Ulcers (DFU). The primary research questions it seeks to address are as follows:
 
 - What are the dynamic characteristics of vascular dynamics at the site of ulcer wounds in
 patients with DFU under high-frame-rate ultrasound imaging?
 
 - Is High-Frequency Contrast-Enhanced Ultrasound (H-CEUS) technology feasible for
 effectively visualizing the microcirculation of ulcer wounds in patients with DFU?
 Participants will Undergo high-frame-rate ultrasound imaging for real-time observation
 of blood perfusion dynamics at the site of ulcer wounds.
 
 Researchers will compare ulcerated sites with normal sites to see whether the use of
 High-Frequency Contrast-Enhanced Ultrasound (H-CEUS) has any discernible impact on the
 visualization of microcirculation in ulcer wounds.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06309082
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06309082 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital of Wenzhou Medical University and is currently Not yet recruiting. The study focuses on Diabetes Mellitus. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.